Statistical approaches for meta-analysis of genetic mutation prevalence.
ascertainment bias
germline mutations
likelihood-based estimation
meta-analysis
prevalence
Journal
Genetic epidemiology
ISSN: 1098-2272
Titre abrégé: Genet Epidemiol
Pays: United States
ID NLM: 8411723
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
28
01
2020
revised:
23
08
2020
accepted:
03
09
2020
pubmed:
2
10
2020
medline:
21
10
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
Estimating the prevalence of rare germline genetic mutations in the general population is of interest as it can inform genetic counseling and risk management. Most studies that estimate the prevalence of mutations are performed in high-risk populations, and each study is designed with differing inclusion criteria, resulting in ascertained populations. Quantifying the effects of ascertainment is necessary to estimate the prevalence in the general population. This quantification is difficult as the inclusion criteria is often based on disease status and/or family history. Combining estimates from multiple studies through a meta-analysis is challenging due to the variety of study designs and ascertainment mechanisms as well as the complexity of quantifying the effect of these mechanisms. We provide guidelines on how to quantify the ascertainment mechanism for a wide range of settings and propose a general approach for conducting a meta-analysis in these complex settings by incorporating study-specific ascertainment mechanisms into a joint likelihood function. We implement the proposed likelihood-based approach using both frequentist and Bayesian methodologies. We evaluate these approaches in simulations and show that the methods are robust and produce unbiased estimates of the prevalence. An advantage of the Bayesian approach is that it can easily incorporate uncertainty in ascertainment probability values. We apply our methods to estimate the prevalence of PALB2 mutations in the United States by combining data from multiple studies and obtain a prevalence estimate of around 0.02%.
Identifiants
pubmed: 33000511
doi: 10.1002/gepi.22364
pmc: PMC10391692
mid: NIHMS1746091
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-170Subventions
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009337
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Nat Rev Cancer. 2004 Mar;4(3):177-83
pubmed: 14993899
Biometrics. 1980 Mar;36(1):27-33
pubmed: 7370373
Am J Med Genet. 1994 Dec 1;53(4):340-7
pubmed: 7864043
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Nat Commun. 2018 Apr 24;9(1):1612
pubmed: 29691392
Theor Popul Biol. 1986 Dec;30(3):388-412
pubmed: 3810507
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Am J Hum Genet. 1988 Oct;43(4):387-95
pubmed: 3177381
Am J Hum Genet. 2000 Mar;66(3):1119-31
pubmed: 10712222
Stat Methods Med Res. 2001 Aug;10(4):277-303
pubmed: 11491414
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):803-11
pubmed: 23456555
Genet Med. 2016 Dec;18(12):1190-1198
pubmed: 27464310
Cancer Med. 2018 Apr;7(4):1349-1358
pubmed: 29522266
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Genet Med. 2015 Jul;17(7):569-77
pubmed: 25356972
Cancer. 2001 Jul 15;92(2):440-5
pubmed: 11466700
Nat Rev Genet. 2013 Jun;14(6):379-89
pubmed: 23657481
Am J Hum Genet. 1995 Jan;56(1):33-43
pubmed: 7825595
J Natl Cancer Inst. 2010 Feb 3;102(3):193-201
pubmed: 20028993
Cancer. 2017 May 15;123(10):1721-1730
pubmed: 28085182
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
Genetics. 1996 Nov;144(3):1215-23
pubmed: 8913762
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
Am J Hum Genet. 1995 Jan;56(1):15-7
pubmed: 7825570
J Genet Couns. 2018 Apr;27(2):381-391
pubmed: 29512060
J Am Stat Assoc. 2005;100(470):399-409
pubmed: 18418465
Am J Hum Genet. 2002 Apr;70(4):886-95
pubmed: 11880949
Am J Hum Genet. 1998 Jan;62(1):145-58
pubmed: 9443863
Breast Cancer Res Treat. 2015 Sep;153(2):435-43
pubmed: 26296701
Cancer Res. 2010 Oct 1;70(19):7353-9
pubmed: 20858716
N Engl J Med. 2014 Oct 23;371(17):1651-2
pubmed: 25337756
Am J Hum Genet. 2000 Dec;67(6):1505-14
pubmed: 11078478
Am J Hum Genet. 1998 Oct;63(4):1202-15
pubmed: 9758615
Int J Cancer. 2017 Aug 15;141(4):750-756
pubmed: 28486781
Stat Med. 1995 Dec 30;14(24):2685-99
pubmed: 8619108
Stat Med. 2017 May 20;36(11):1715-1734
pubmed: 28124446
Stat Med. 2003 Jun 15;22(11):1837-48
pubmed: 12754719
Am J Hum Genet. 1996 Sep;59(3):726-30
pubmed: 8751874
J Med Genet. 2005 Jun;42(6):491-6
pubmed: 15937084
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
Am J Hum Genet. 1999 Apr;64(4):963-70
pubmed: 10090881
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
J Genet Couns. 2018 Sep;27(5):1187-1199
pubmed: 29500626
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
Genet Med. 2018 Jan;20(1):119-127
pubmed: 28726808
Stat Appl Genet Mol Biol. 2004;3:Article21
pubmed: 16646800
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
Am J Hum Genet. 1997 Mar;60(3):505-14
pubmed: 9042909
Hum Hered. 1973;23(2):105-12
pubmed: 4756850
J Med Genet. 2011 Aug;48(8):523-5
pubmed: 21415078
J Clin Oncol. 2016 Aug 10;34(23):2750-60
pubmed: 27269948
J Clin Oncol. 2017 Oct 20;35(30):3382-3390
pubmed: 28767289
Nat Genet. 1996 Oct;14(2):185-7
pubmed: 8841191